Most shareholders have been waiting for announcements of the IND...

Most shareholders have been waiting for announcements of the IND application approval/disapproval (phase II trials).
An acceptance/presentation of research papers at a conference is one of easiest ways to add to researcher's profile.
Anyway, I congratulate on the acceptance of presentation of the research paper. However, VLA is not a pure research institute but a company for commercialising its research result.

As a non-researcher, when you need to know how good (much breakthrough) a research result is, you may judge it by the impact factor of journals in which the result has been accepted/published. Two of the best journals are Nature and Science.

Shareholders may be disappointed with today's announcement because they have expected the IND approval but lack of info of it.
VLA should inform shareholders some more details what is going on with FDA. Why is delayed?
VLA should concentrate more on the IND application rather some different research results (although researchers need to publish something to get fund from some organisations)?

My view only.

DYOR